Janux Therapeutics, Inc. (JANX) research
Janux Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $16.93
- As of
Janux Therapeutics, Inc. (JANX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
As of . Source: SEC EDGAR filings for JANX. Method and limitations.
Share the JANX intelligence card
See the full JANX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for JANX on one page. Preview it with sample data, then open it live with a free account.
Preview the JANX dossierActive signals for JANX
- highCONSENSUS_BUY
4 tracked funds increased JANX this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased JANX this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +72% to JANX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 69% of JANX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 54% of JANX (2026Q2)
FREE, NO ACCOUNT
Every signal on JANX, as it fires
You are seeing 5 of 16 signals recorded on JANX since 2026-06-02.
The five above landed across 2 days. The other 11 were recorded on 4 other days. 8 of the 16 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in JANX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 47103J105 · 2026Q2 | $30.6M | 0.03% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 47103J105 · 2026Q2 | $18.5M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 47103J105 · 2026Q2 | $18.4M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 47103J105 · 2026Q2 | $16.8M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 47103J105 · 2026Q2 | $7.7M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, JANX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
JANX against its peers
JANX's operating margin of -1576.7% ranks in the 6th percentile of 8 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | JANX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 10.0M USD | 116M USD | 6 | 8 |
| Operating margin | -1576.7% | -26.9% | 6 | 8 |
| Net margin | -1136.3% | -23.2% | 6 | 8 |
| Return on equity | -11.9% | -41.0% | 81 | 12 |
Peers (16): GLUE, MLTX, SVRA, CRVS, MGTX, ABUS, MNKD, VOR, KURA, CGEM, JBIO, RIGL, TBPH, ARDX, SANA, SGP. Left out: ODTX (no annual filing), ANL (period gap), SPTX (no annual filing), AKTS (no annual filing), SLBT (no annual filing), APMD (no annual filing), LTGO (no annual filing), IVA (period gap), HELP (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (JANX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more JANX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to JANXand get the insider, 13F, options, and confluence read in one view.